采用酶联免疫法测定28例肝硬化,20例肝癌患者血清及腹水中sIL-2R的含量,结果表明肝硬化、肝癌中血清sIL-2R含量明显高于正常对照组(P<0.05,P<0.01),肝癌组血清及腹水中sIL-2R均明显高于肝硬化组(P<0.01),提示二者均存在免疫功能紊乱,腹水中sIL-2R测定有利于肝癌早期诊断。 The levels of sIL-2R in serum and ascites in 28 cases of liver cirrhosis and 20 cases of hepatocellular carcinoma were measured by enzyme-linked immunosorbent assay. The results showed that serum sIL-2R levels in liver cirrhosis and liver cancer were significantly higher than those in normal controls (P<0.05, P< 0.01) The serum and ascitic fluid sIL-2R in HCC group were significantly higher than those in liver cirrhosis group (P<0.01), suggesting that both of them have immune function disorder. The determination of sIL-2R in ascites is beneficial to the early diagnosis of HCC.